Updated July 3 at 9:03pm
Biotechnology
41 results total, viewing 11 - 20
The first two patients in IlluminOss Medical Inc.’s U.S. Lightfix clinical trial for the treatment of impending and pathologic fractures have been successfully treated at the Marshall University Joan C. Edwards School of Medicine. more
The Defense Threat Reduction Agency is investing $5.2 million for the development of a new type of vaccine against Q fever, and a local company is involved in the effort. more
Moderna Therapeutics has announced another record venture capital investment: $450 million. more
(Updated, 5:14 p.m.) A Cherrystone Angel Group portfolio business has entered into an acquisition agreement of $140 million with a European buyer specializing in bio-analytical testing and genomic services. more
A Japanese biopharmaceutical company has contracted to begin using a protein-screening interface developed by Providence-based EpiVax Inc. more
NsGene Inc.’s innovative brain-repair therapy couldn’t have come at a better time, as one of the neurodegenerative diseases it would treat – Parkinson’s disease – has gotten a lot of press lately. more
An investor in two large Bay State health care companies involved in separate mergers said he doesn’t expect the U.S. Treasury’s recently announced measures aimed at cracking down on corporate tax inversions to derail those plans, the Boston Business Journal reported. more
Brown University has leased its 4,000-square-foot building at 349 Eddy St. to biotechnology firm ProThera Biologics. more
ProThera Biologics has appointed Denice M. Spero as president and chief business officer. more
Amy Orlick Berman has been appointed IlluminOss Medical’s vice president of clinical affairs. more
« Prev | 1 | 2 | 3 | 4 | 5 Next »